AirSculpt Technologies Inc

AirSculpt Technologies Inc (AIRS) Stock Analysis

$2.600

-0.010 (-0.38%)At close

Loading chart…
High
2.730
Open
2.590
VWAP
2.60
Vol
1.11M
Mkt Cap
236.04M
Low
2.480
Amount
2.89M
EV/EBITDA, TTM
9.56

AirSculpt Technologies, Inc. is engaged in providing body contouring treatment. The Company's treatment procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for healing with minimal bruising, tighter skin, and precise results. It offers a range of fat removal procedures across treatment areas. It also offers fat transfer procedures that use the patient’s own fat cells to enhance the breasts, buttocks, hips or other areas and do not require silicone or foreign materials to be implanted. Its body contouring procedures include the Power BBL, a Brazilian butt lift procedure, the Up a Cup, a breast enhancement procedure, and the Hip Flip, an hourglass contouring procedure. It also offers AirSculpt +, which permanently removes fat and tightens the skin. Its treatment combines helium gas and radiofrequency energy to create a plasma equipped to correct sagging skin and restore a youthful, natural appearance.

airsculpt.com

AI analysis of AirSculpt Technologies Inc (AIRS)

hold

Airsculpt Technologies Inc is currently trading at $2.60, which is significantly below the analyst price target of $4.50, suggesting potential upside. However, the RSI is at 28.69, indicating the stock is oversold, but the recent 5-day change is -5.11%, showing continued downward pressure. The main risk is the company's declining revenue, as Q2 revenue dropped to $42.9 million, down 3% year-over-year, which could affect investor confidence.

Valuation Metrics

The current forward P/E ratio for AirSculpt Technologies Inc (AIRS) is 0.00, compared to its 5-year average forward P/E of 63.22.

Forward P/E

Fair
5Y Average P/E
63.22
Current P/E
0.00
Overvalued
358.74
Undervalued
-232.30

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
18.82
Current EV/EBITDA
9.56
Overvalued
38.66
Undervalued
-1.01

Forward P/S

Fair
5Y Average P/S
2.04
Current P/S
1.21
Overvalued
3.10
Undervalued
0.99

Alphio AI Price Scenarios for AIRS

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%AIRS

$4.14

Scenario price

B

Base

Base · 50%AIRS

$3.25

Scenario price

B

Bear

Bear · 25%AIRS

$2.81

Scenario price

Events Timeline

2026-08-10 (ET)

06:30:00

2026 Revenue Consensus at $153.19M, Adjusted EBITDA View Reduced to $12M-$14M

06:30:00

Company Reports Q2 Revenue of $42.9M, Below Expectations

2026-05-08 (ET)

06:40:00

Reaffirms FY26 Adjusted EBITDA View of $15M-$17M

06:40:00

AirSculpt Reports Q1 Revenue of $39.39M

2026-04-02 (ET)

16:40:00

Major U.S. Averages Mixed as Oil Prices Rise to $111.54

News

AIRS FAQ — answered by Alphio AI

AirSculpt Technologies, Inc. is engaged in providing body contouring treatment. The Company's treatment procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for healing with minimal bruising, tighter skin, and precise results. It offers a range of fat removal procedures across treatment areas. It also offers fat transfer procedures that use the patient’s own fat cells to enhance the breasts, buttocks, hips or other areas and do not require silicone or foreign materials to be implanted. Its body contouring procedures include the Power BBL, a Brazilian butt lift procedure, the Up a Cup, a breast enhancement procedure, and the Hip Flip, an hourglass contouring procedure. It also offers AirSculpt +, which permanently removes fat and tightens the skin. Its treatment combines helium gas and radiofrequency energy to create a plasma equipped to correct sagging skin and restore a youthful, natural appearance. It operates in the Healthcare sector (SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE industry).

Airsculpt Technologies Inc is currently trading at $2.60, which is significantly below the analyst price target of $4.50, suggesting potential upside. However, the RSI is at 28.69, indicating the stock is oversold, but the recent 5-day change is -5.11%, showing continued downward pressure. The main risk is the company's declining revenue, as Q2 revenue dropped to $42.9 million, down 3% year-over-year, which could affect investor confidence.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める